Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.53 |
| ▸ | RRM2 | P31350 | 2/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477726 | 0.92 | CTSL (0.45) | CTSLRRM2RRM1RRM2BCISD1 | |
| SCHEMBL18479608 | 0.86 | CTSL (0.40) | CTSLRRM2RRM1RRM2BCISD1 | |
| SCHEMBL18477861 | 0.83 | CTSL (0.37) | CTSL | |
| SCHEMBL20414239 | 0.82 | MAPT (0.40) | CTSLMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL18476984 | 0.82 | NPC1 (0.36) | CTSLMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL18477885 | 0.81 | ALDH1A1 (0.41) | MEN1GAAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL18477166 | 0.80 | HSP90AA1 (0.38) | CTSLMEN1KMT2AKDM4E | |
| SCHEMBL18477864 | 0.80 | GAA (0.37) | CTSLGAAALDH1A1L3MBTL1LMNA | |
| SCHEMBL20414240 | 0.80 | ALDH1A1 (0.40) | CTSLGAAALDH1A1L3MBTL1LMNA | |
| SCHEMBL18477882 | 0.80 | ALDH1A1 (0.44) | MEN1GAAKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | NANTBIO, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| WO-2017024315-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | TPMT, MKI67, TST | CTSL 2976/4885RRM2 1270/4885RRM1 1462/4885 |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | TPMT, MKI67, TST | CTSL 2976/4885RRM2 1270/4885RRM1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.